In this article, we present a narrative review on the use of inositol in the treatment of polycystic ovary syndrome (PCOS). Of the different inositols that exist, only myo-inositol (MYO) and D-chiro inositol (DCI) have been studied in the treatment of ...
Iñaki Lete +4 more
doaj +1 more source
D-Chiro-Inositol and Myo-Inositol Induce WAT/BAT Trans-Differentiation in Two Different Human Adipocyte Models (SGBS and LiSa-2). [PDF]
Monastra G +5 more
europepmc +1 more source
Management of polycystic ovary syndrome among Indian women using myo-inositol and D-chiro-inositol. [PDF]
Vyas L +6 more
europepmc +1 more source
D-Chiro-Inositol improves testosterone levels in older hypogonadal men with low-normal testosterone: a pilot study. [PDF]
Nordio M +3 more
europepmc +1 more source
OBJECTIVES: Asprosin, a novel adipokine primarily secreted by white adipose tissue, has been implicated in the pathogenesis of insulin resistance and metabolic dysfunction.
Ozlen Emekci Ozay +4 more
doaj +1 more source
Differential Gene Expression and Biological Analyses of Primary Hepatocytes Following D-Chiro-Inositol Supplement. [PDF]
Cheng F +7 more
europepmc +1 more source
Effects of Oral Supplementation with Myo-Inositol and D-Chiro-Inositol on Ovarian Functions in Female Long-Term Survivors of Lymphoma: Results from a Prospective Case-Control Analysis. [PDF]
Dellino M +18 more
europepmc +1 more source
High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries. [PDF]
Bevilacqua A +5 more
europepmc +1 more source
D-chiro-inositol Induces Ovulation in Non-Polycystic Ovary Syndrome (PCOS), Non-Insulin-Resistant Young Women, Likely by Modulating Aromatase Expression: A Report of 2 Cases. [PDF]
Bezerra Espinola MS +5 more
europepmc +1 more source
Comparison of Clinical, Metabolic and Hormonal Effects of Metformin Versus Combined Therapy of Metformin With Myoinositol Plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial. [PDF]
Bahadur A +7 more
europepmc +1 more source

